RxDoctor Payments Data

Morgan Needham, PA

Medical · Allentown, PANPI 1275082307

Payments from drug & device makers

$2,239in general payments, 2019–2025

Across 24 payments — averaging $93.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$761
  • AbbVie$631
  • Avita Medical Americas, LLC$288
  • AstraZeneca$143
  • Neurelis, Inc.$125
  • GSK$125
  • plus $167 from 2 others

What the payments were for

  • Food & beverage$2,239100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)9$761
AbbVie6$631
Avita Medical Americas, LLC3$288
AstraZeneca2$143
Neurelis, Inc.1$125
GSK1$125
Johnson & Johnson1$93
Novartis1$74

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,239 in reported general payments places this provider in the 80th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$129,677
Medicare patients
255
Services billed
4,775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab31$252,119
Xeljanz XrTofacitinib Citrate35$190,486
Enbrel SureclickEtanercept26$189,491
RinvoqUpadacitinib21$141,791
Orencia ClickjectAbatacept20$113,432
EnbrelEtanercept11$78,759
OtezlaApremilast14$68,391
Hydroxychloroquine Sulfate268$14,494
RasuvoMethotrexate/Pf14$7,866
MethotrexateMethotrexate Sodium207$6,668
Celecoxib98$2,543
Leflunomide42$2,354
Prednisone182$1,809
Pilocarpine Hcl18$1,467
Diclofenac Sodium44$1,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$761$147,15025 claims
AbbVieRinvoq$631$141,79121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →